Genetic complexity impacts the clinical outcome of follicular lymphoma patients

María García-Álvarez1, Sara Alonso-Álvarez2, Isabel Prieto-Conde2, Cristina Jiménez1, M. Eugenia Sarasquete3, M. Carmen Chillón1, Alejandro Medina1, Ana Balanzategui1, Rebeca Maldonado1, Alicia Antón1, Marta Rodríguez3, Oscar Blanco3, Luis G. Díaz1, Pilar Tamayo1, Pedro Blanco3, Carmen Esteban1, Verónica González-Calle1, Noemí Puig1, Norma Gutiérrez1, Alejandro Martín1, Ramón García-Sanz1, Marcos González1, M. Dolores Caballero1 y Miguel Alcoceba1

Dear Editor,

Follicular lymphoma (FL) is the second most common non-Hodgkin lymphoma (NHL, 20–30%) after diffuse large B-cell lymphoma (DLBCL). Despite the introduction of rituximab and the high response rate to first-line treatment, approximately 20% of the FL patients relapse or progress within 2 years of receiving first-line therapy. Therefore, the major challenge is finding biomarkers that identify high-risk patients at diagnosis.

Qu et al. reported an association between increased genomic complexity, a concept based on copy-number aberrations (CNAs) and copy neutral loss of heterozygosity (cnLOH), and poor outcome in FL [1]. However, the concept of genetic complexity based on the number of mutated genes has not been analyzed in FL patients yet.

The aim of the present study was to analyze in detail the genetic landscape and genetic complexity by next-generation sequencing (NGS), defined by the number of mutated genes, in a FL series to improve our understanding of the biology of FL and its impact on the clinical outcome of the patients. See Supplementary Materials for details of methods.

A total of 83 FL grade I–IIIA patients diagnosed at the University Hospital of Salamanca between January 2000 and December 2017 were retrospectively included. The study was approved by the local Ethical Committee, in accordance with Spanish law and the Declaration of Helsinki. Written informed consent was obtained from all the patients. Clinical characteristics of the cohort are described in Table 1.

We explored in patients who received rituximab-based immunochemotherapy (R-ICT, n = 47) the influence of clinical-biological variables at diagnosis on the following clinical endpoints: (i) complete response rate at 30 months (CR30) [2], defined as complete response 30 months after the first day of induction treatment; (ii) failure-free survival (FFS), defined as less than a partial response at the end of induction, relapse, progression, or death [3]; and (iii) overall survival (OS), defined as the time from the date of diagnosis of FL to that of death from any cause.

We identified 56 mutated genes in our FL series and 548 somatic nonsynonymous variants. FL patients harbored a median of 5 mutated genes (range 1–12) and 6 mutations (range 1–18) per case in our series. Fourteen genes were mutated with a frequency greater than 10%: CREBBP 63.9% (n = 53), KMT2D/MLL2 55.4% (n = 46), BCL2 41% (n = 34), TNFRSF14 27.7% (n = 23), EZH2 22.9% (n = 19), STAT6 19.3% (n = 12), ARID1A 18.1% (n = 15), FOXO1 18.1% (n = 15), CARD11 14.5% (n = 12), EP300 14.5% (n = 12), GNAI3 13.2% (n = 11), IRF8 12% (n = 10), SMARCA4 12% (n = 10), and HIST1H1E 10.8% (n = 9) (Supplementary Fig. S1), being a subset of mutations clustered at known domains or hotspots (Supplementary Fig. S2).

The clinical impact of the 14 mutated genes with frequency >10% were explored. We first compared the clinical characteristics at diagnosis between groups to avoid potential biases in the analyses. CREBBP mutations were more frequently observed in younger FL patients.
Response after induction therapya

| Variable                                      | Training cohort n (%) |
|-----------------------------------------------|-----------------------|
| Age, years (median, range)                    | 62.5 (19–86)          |
| Sex F/M                                       | 46/37                 |
| Histological gradea                          |                       |
| 1                                             | 30 (38.0)             |
| 2                                             | 40 (50.6)             |
| 3A                                            | 9 (11.4)              |
| FLIPIb                                        |                       |
| 0-1 (Low risk)                                | 24 (32.0)             |
| 2 (Intermediate risk)                         | 17 (22.7)             |
| 3-5 (High risk)                               | 34 (45.3)             |
| Ann Arbora                                    |                       |
| I                                             | 10 (14.1)             |
| II                                            | 9 (12.7)              |
| III                                           | 7 (9.9)               |
| IV                                            | 45 (63.4)             |
| First-line therapy                            |                       |
| Never treated                                 | 10 (12.0)             |
| Palliative care                               | 4 (4.8)               |
| Rituximab-based ICT                           | 47 (56.6)             |
| R-CHOP                                        | 33 (39.8)             |
| R-Bendamustine                                | 3 (3.6)               |
| R-CVP                                         | 3 (3.6)               |
| R-FC                                          | 4 (4.8)               |
| R-Lenalidomide                                | 4 (4.8)               |
| CT without rituximab                          | 13 (15.7)             |
| CHOP                                          | 11 (13.3)             |
| Other                                         | 2 (2.4)               |
| Radiotherapy alone or with rituximab           | 6 (7.2)               |
| Rituximab alone                               | 3 (3.6)               |
| Maintenance with rituximabb                   | 37 (53.6)             |
| Response after induction therapya             |                       |
| CR                                            | 37 (53.6)             |
| PR                                            | 28 (40.6)             |
| NR/failure                                    | 4 (5.8)               |
| CR30a                                         | 33 (47.8)             |

*Histological grade was available for 79 (95%) patients; FLIPI was available for 75 (99%) patients; Ann Arbor was available for 71 (86%) patients; Maintenance, response and CR30 were calculated for 69 (83%) patients. CHOP cyclophosphamide, doxorubicin, vincristine, prednisone; CR complete response, CR30 complete response 30 months after the date induction treatment began, CT chemotherapy, CVP cyclophosphamide, vincristine, prednisone; FLIPI FL International Prognosis Index, ICT immunochemotherapy, NR no response, PR partial response, R rituximab.

(<60 years, \(P < 0.05\)). No other differences were observed for individual gene mutations regarding clinical characteristics of patients.

Regarding the clinical endpoints, mutations in \(EZH2\) were significantly associated with the presence of CR at 30 months (100% vs. 53.3%, \(P < 0.05\)). Considering FFS, those FL patients with \(FOXO1\) mutations (25% vs. 68%, \(P < 0.05\)) showed significantly shorter FFS at 5 years than the remaining patients. No other gene mutations were associated with CR30, FFS, or OS at 5 years.

All seven genes included in the m7-FLIPI clinical-genetic risk model described by Pastore et al. [3] were targeted by our NGS design, and therefore this model could be applied in 74 patients (89%). This score reclassified 17 high-risk FLIPI patients (23%) into the low-risk group. In our series, lower number of cases in CR30 (33% vs. 71%, \(P > 0.05\)), shorter FFS at 5 years (36% vs. 74%, \(P > 0.1\)), and shorter OS at 5 years (64% vs. 82%, \(P > 0.1\)) were found in high-risk m7-FLIPI patients although the differences were not statistically significant (Supplementary Fig. S3). In this series, FLIPI index was able to distinguish two groups with different OS at 5 years (69% vs. 88%, \(P < 0.05\)) (Supplementary Fig. S3).

In relation to genetic complexity, we observed a continuous FFS decrease as the number of mutated genes increased. Thus, we identified two groups with different FFS: 53 patients (63.9%) with ≤5 mutated genes and 30 patients (36.1%) with >5 mutated genes, which exactly matches with the median number of mutated genes and the result of the ROC analysis.

These two groups did not show significant differences in clinical characteristics including histological grade, FLIPI, and treatment requirement among others (Supplementary Table S1). By contrast, mutated genes showed a different distribution in both groups, underlining the high frequency of \(BCL2\) (63% vs. 28%, \(P < 0.01\)), TNRFSF14 (43% vs. 19%, \(P < 0.05\)), \(ARD1A\) (30% vs. 11%, \(P < 0.05\)), \(FOXO1\) (33% vs. 9%, \(P < 0.05\)), \(GNA13\) (27% vs. 6%, \(P < 0.05\)), \(IRF8\) (27% vs. 4%, \(P < 0.01\)), and \(MEF2B\) (23% vs. 0%, \(P < 0.01\)) genes in group with >5 mutated genes.

A strong association was observed between >5 mutated genes and a lower number of cases in CR at 30 months as compared to ≤5 mutated genes (29% vs. 83%, \(P < 0.01\)). Moreover, patients with >5 mutated genes had a higher risk of treatment failure, since these patients showed shorter FFS at 5 years than those with ≤5 mutated genes (30% vs. 82%, \(P < 0.001\)) (Fig. 1A). Finally, patients with >5 mutated genes displayed shorter OS at 5 years than patients with ≤5 mutated genes (58% vs. 88%, \(P < 0.05\)) (Fig. 1B).

In the multivariate analysis, including FLIPI and m7-FLIPI as co-variables besides those statistically significant in univariate analysis, the only variable independently associated with shorter FFS was having >5 mutated genes...
In terms of OS, to present >5 mutated genes (HR: 5.4, 95% CI: 1.5–19.6) and high-risk FLIPI (HR: 7.2, 95% CI: 1.3–39.1) at the time of diagnosis were independently associated with shorter OS (Supplementary Table S2).

In this work, we showed for the first time the association of genetic complexity, defined by the number of mutated genes, and FL outcome, independently of FLIPI. Genetic complexity in our study was defined as >5 mutated genes among 66 and it was associated with a poor outcome assessed by low number of cases in CR at 30 months, poor FFS, and short OS. In a very recent work, an increased genomic complexity defined by the number of CNAs was associated with worse FFS and OS in FL [1]. The impact of the number of mutations or the number of CNAs in the clinical course of patients has been reported in other hematological malignancies [9, 10].

Even associated to genetic complexity, we pointed out the association of FOXO1 mutations with adverse outcome. FOXO1 mutations had already been correlated to worse FFS in FL [3], and worse OS in DLBCL [11], and they were found at high prevalence in relapsed/refractory FL [12], thus supporting its adverse role in FL outcome. Finally, EZH2 mutations were associated to the persistence of complete response after 30 months from therapy initiation (CR30), although they were equally distributed between genetic complexity groups, thus suggesting a subgroup of patients with better prognosis independently of the genetic complexity. This is in line with prior studies that associate EZH2 mutations with favorable prognosis in FL [13–15].

In summary, our study has increased the knowledge of the FL biology through the characterization of the mutational landscape of a representative series of FL patients,
and allowed to confirm the dependence of the tumor germinal center B-cell on alterations in genes involved in epigenetic modification, signaling, and transcription factors. Our results identified genetic alterations associated with prognosis in a cohort treated with chemoimmunotherapy based on rituximab. The most outstanding result, however, was that genetic complexity related with lower number of CR30 cases, worse FFS, and shortened OS, independently of FLIPi. Although the small number of patients could limit some analysis and further validation is required, we have shown that genetic complexity constitutes a promising robust tool that may be incorporated into risk predictive models, and may improve risk classification of FL to help in the development of new risk-adapted therapies.

Acknowledgements

This work was partially supported by the Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Economy and Competitiveness P115/01393, P118/00410, CIBERONC-CB16/12/00233, and “Una manera de hacer Europa” (Innocompass: CEI-2010-1-0010), the Education Council or Health Council of the Junta de Castilla y León (CAS102P17, GRS 1180/A/15), Spanish Association Against Cancer (AECC; PROYE18020BEA), and Gilead Sciences (GLD17/00334). C.J., M.E.S., and A.Me. are supported by the ISCIII (CD19/00030, CPII18/00028, and FI19/00320). M.G.A., IPC, and C.J were supported by the Spanish Society of Hematology Foundation (FEHH). All Spanish funding is co-sponsored by the European Union FEDER program. The authors wish to thank Ana Rodríguez, Montserrat Hernández-Ruano, Estrella Amés, Inmaulucada Sánchez, Rocío Corral and Francisco Boix (University Hospital of Salamanca, Spain) for their technical support, and Sara Bonilla, for helping with the mutation plots. The authors are also very grateful to the patients who participated in this study.

Author details

1Department of Hematology, University Hospital of Salamanca (HU/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain. 2Department of Hematology, Central University Hospital of Asturias (HUCA), Oviedo, Spain. 3Department of Pathology, University Hospital of Salamanca (HU/IBSAL), Salamanca, Spain. 4Department of Nuclear Medicine, University Hospital of Salamanca (HU/IBSAL), Salamanca, Spain. 5Department of Otorhinolaryngology, University Hospital of Salamanca (HU/IBSAL), Salamanca, Spain. 6Department of General and Gastrointestinal Surgery, University Hospital of Salamanca (HU/IBSAL), Salamanca, Spain

Author contributions

M.G.A. and M.A. conceived and designed the study. M.G.A., S.A.A., I.P.C., C.J., A.Me., A.B., R.M., and A.A. produced the molecular results. M.R. and O.B. were responsible for the clinical data. M.G.A. and M.A. conceived and designed the study. M.G.A., S.A.A., I.P.C., C.J., M.E.S., A.Me., and V.G.C. are or were supported by the Spanish government (ISCIII and/or FEHH). Consulting fees and/or non-financial support were reported from Abbvie (M.G., M.A., M.D.C.), Amgen (NP., M.D.C.), Binding Site (N.P.), Bristol-Myers Squibb (V.G.C., N.P., A.M., R.G.S., M.D.C.), Eusa Pharma (A.M.), Gilead (AM, M.G., M.D.C.), iQone Healthcare (AM), Incyte (R.G.S.), Janssen (V.G.C., NP., A.M, R.G.S, M.G., M.D.C., M.A.), Kite (M.D.C.), Kyowa Kirin (AM), MSD (M.D.C.), Novartis (S.A.A., M.D.C.), Prothena (V.G.C.), Roche (A.M., M.G., M.D.C., M.A.), Servier (AM, M.D.C.), Takeda (NP., R.G.S., M.D.C.), and Weber (NP). The remaining authors have no relevant conflicts of interest to disclose. R.G.S. is the president of the Spanish Society of Hematology.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

accompanies this paper at (https://doi.org/10.1038/s41408-020-00395-y).

References

1. Qu, X et al. Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study 50016. Blood 133, 81–89 (2019).
2. Shi, Q et al. Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials. J. Clin. Oncol. 35, 552–560 (2017).
3. Pastore, A. et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 16, 1111–1122 (2015).
4. Green, M. R. et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood 121, 1604–1611 (2013).
5. Kysiaś, K. et al. Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood 129, 473–483 (2017).
6. Korf, K., Ali, S., Heward, J. A. & Fitzgibbon, J. Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations. Epigenetics 12, 370–377 (2017).
7. Kuppers, R. & Stevenson, F. K. Critical influences on the pathogenesis of follicular lymphoma. Blood 131, 2297–2306 (2018).
8. Lockmer, S. et al. M7-FLIPi is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy. Br. J. Haematol. 188, 259–267 (2020).
9. Puente, X. S. et al. Non-coding recurrent mutations in chronic lymphocytic leukemia. Nature 526, 519–524 (2015).
10. Piojo-Conde, M. I. et al. Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients. Br. J. Haematol. 189, 718–730 (2020).
11. Trih, D. L. et al. Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood 121, 3666–3674 (2013).
12. Umakanthan, J. M. et al. Phase II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma. Br. J. Haematol. 184, 744–752 (2019).
13. Bodor, C. et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 122, 3165–3168 (2013).
14. Weigert, O. & Wenstrom, D. M. The promises and challenges of using gene mutations for patient stratification in follicular lymphoma. Blood 130, 1491–1498 (2017).
15. Huett, S. et al. EZH2 alterations in follicular lymphoma: biological and clinical correlations. Blood Cancer J. 7, e555 (2017).